What metastases will occur after platinib resistance?

Platinib, as a tyrosine kinase inhibitor (TKI) targeting RETrearranged non-small cell lung cancer (NSCLC), has shown significant efficacy in clinical treatment. However, as treatment progresses, some patients may develop resistance to platinib and face the risk of disease progression and metastasis.

The resistance mechanisms of platinib are complex and diverse, and may involve the activation of multiple pathways or gene mutations other than the RET gene. These changes may render tumor cells less sensitive to drugs, thereby promoting disease progression. As the disease progresses, tumor cells may spread to other parts of the body through the blood or lymphatic system, forming metastases.

1.Intrapulmonary metastasis: NSCLC Intrapulmonary metastasis is most common in patients with platinib resistance. This manifests as new tumor lesions in the lungs, which may lead to further impairment of the patient's respiratory function.

2.Bone metastasis: Bone metastasis is also one of the common metastasis modes in NSCLC patients. Tumor cells invade the skeletal system, which may cause bone pain, fractures and other symptoms, seriously affecting the patient's quality of life.

3.Brain metastasis: After resistance to platinib, some patients may also develop brain metastasis. Due to the existence of the blood-brain barrier, many drugs cannot effectively penetrate into brain tissue, making the treatment of brain metastases particularly difficult. Brain metastasis may cause symptoms such as increased intracranial pressure such as headache, nausea, and vomiting, and even endanger the patient's life.

In order to reduce the risk of metastasis after platinib resistance, patients should undergo regular comprehensive physical examinations, including imaging examinations such as lung CT, bone scan, and brain MRI. These examinations help to detect potential metastatic lesions in time and provide opportunities for early intervention and treatment.

For patients who have metastasized, doctors should adjust the treatment plan according to the specific situation. This may include changing to another validTKIStrategies such as drugs, combination chemotherapy, or immunotherapy to slow disease progression and improve patients’ quality of life.